| content | |||||||||||||||||||||||||||||||||||||||||||
 |
|
|
Amrubicin
|
|
| Systematic (IUPAC) name | |
| (7S,9S)-9-Acetyl-9-amino-7-[(2S,4S,5R)-4,5-dihydroxyoxan-2-yl]oxy-6,11-dihydroxy-8,10-dihydro-7H-tetracene-5,12-dione | |
| Identifiers | |
| CAS number | |
| ATC code | ? |
| PubChem | |
| Chemical data | |
| Formula | C25H25NO9 |
| Mol. mass | 483.46 g/mol |
| SMILES | & |
| Pharmacokinetic data | |
| Bioavailability | ? |
| Metabolism | ? |
| Half life | ? |
| Excretion | ? |
| Therapeutic considerations | |
| Pregnancy cat. |
? |
| Legal status |
℞ Prescription only |
| Routes | IV |
Amrubicin (INN; previously known as SM-5887) is an anthracycline used in the treatment of lung cancer.1 It is marketed in Japan since 2002 by Sumitomo Pharmaceuticals under the brand name Calsed.2
It has also been studied for the treatment of bladder carcinoma3 and gastric cancer.4
References
- ^ Ueoka H, Ohnoshi T, Kimura I (November 1992). "[New anthracycline analogues in the treatment of lung cancer]" (in Japanese). Gan To Kagaku Ryoho 19 (13): 2146–9. PMID 1332624.
- ^ Sumitomo Pharmaceuticals Co., Ltd. (2003). "CALSED for Injection (English)". Retrieved on 2008-08-17.
- ^ Ohmori H, Tsushima T, Kobashi K (April 1996). "[Experimental studies on intravesical instillation of SM-5887, a novel anthracycline derivative for treatment of bladder carcinoma]" (in Japanese). Gan To Kagaku Ryoho 23 (5): 601–6. PMID 8678519.
- ^ Tsushima K, Sakata Y, Munakata A, et al (June 1991). "[A phase II study of SM-5887 for advanced gastric cancer]" (in Japanese). Gan To Kagaku Ryoho 18 (7): 1151–4. PMID 1647150.
